Engflag

Lexiscan

Quick links to important sections

Lexiscan

Selected form

Lexiscan_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexiscan

Property Description
Active ingredient Regadenoson
Form Solution for intravenous injection
Pharmacological Class Coronary Vasodilator, Selective A2A Receptor Agonist
Common Use Diagnostic aid for Myocardial Perfusion Imaging (MPI)
Origin Synthetic nucleoside derivative

What Type of Medicine is Lexiscan (Regadenoson)?

Lexiscan is a prescription-only medication classified as a Pharmacologic Stress Agent and a Coronary Vasodilator. Its active ingredient, Regadenoson, is the International Nonproprietary Name (INN) for a specialized compound. The drug is clinically recognized for its role as an aid in the diagnostic evaluation of the heart.

This medicine belongs to the class of selective Adenosine A2A Receptor Agonists. Regadenoson is a synthetic nucleoside derivative distinguished by its high selectivity. This intentional targeting of the A2A receptor is crucial as it minimizes off-target activity, focusing the vasodilatory effect on the coronary arteries.

Regadenoson Composition, Origin, and Form

The medicinal entity, Regadenoson (C15H18N8O5), functions as a single-ingredient product. Lexiscan is supplied as a sterile, clear, and colorless solution for injection in an aqueous sterile solution intended for intravenous administration. This is a deliberate formulation choice, optimizing for the rapid, controlled delivery required during the diagnostic procedure.

What is the General Purpose of Lexiscan?

The general purpose of Lexiscan is to serve as a necessary diagnostic aid during Radionuclide Myocardial Perfusion Imaging (MPI) procedures. As a pharmacologic stress agent, its action induces coronary hyperemia induction, which is a rapid and significant increase in blood flow within the coronary arteries. Regadenoson is a highly selective and potent vasodilator used for pharmacologic stress testing.

Lexiscan is specifically intended for use in adult patients who are physically unable to undergo adequate exercise stress testing, providing a reliable, non-exercise alternative for diagnostic evaluation. A typical scenario involves using the drug to help assess blood flow in the heart muscle when a patient has mobility issues or other health conditions precluding strenuous activity.

What side effects are possible with Lexiscan?

The safety profile of Lexiscan (Regadenoson) is strictly defined by regulatory documents, distinguishing between highly common, transient events and rare, clinically serious adverse reactions.

Adverse Reactions and Frequency

The most frequently documented side effects (classified as Very Common or Common in regulatory labeling, incidence ge5%) primarily affect the cardiac, vascular, and nervous systems. These reactions include dyspnea (shortness of breath), headache, flushing, chest discomfort, dizziness, nausea, and various changes on the electrocardiogram (ECG). These effects typically begin soon after dosing and are transient, generally resolving within approximately 15 minutes of administration.

System-Organ Class Common Adverse Reactions (Examples)
Cardiac Disorders Chest discomfort, Angina, ECG changes
Nervous System Headache, Dizziness, Dysgeusia
Vascular Disorders Flushing, Hypotension/Hypertension
Respiratory Disorders Dyspnea, Bronchoconstriction

Serious Adverse Reactions

Official regulatory labels document serious adverse reactions which may occur, including fatal and nonfatal Myocardial Infarction (MI), Cardiac arrest, life-threatening Ventricular arrhythmias, and high-grade Atrioventricular (AV) block (sometimes progressing to Asystole). Rare but severe Hypersensitivity reactions, including Anaphylaxis, and Cerebrovascular accidents (Stroke) have also been reported.

Safety Restrictions

Use is formally contraindicated in patients with second- or third-degree AV block or sinus node dysfunction, unless a functioning artificial pacemaker is present. Furthermore, patients with signs of acute myocardial ischemia are considered to be at a greater risk of serious cardiovascular events. Methylxanthines (such as caffeine or theophylline) must be avoided prior to administration as they interfere with the drug's effect and may increase the risk of adverse events. No dosage adjustment is specified as necessary for older adults or in patients with renal or hepatic impairment.

Overdose and Emergency Response

Overdose with Lexiscan (Regadenoson) is primarily characterized by an intensification of its expected effects on the cardiovascular system. Official regulatory information documents that manifestations typically include severe hypotension (significantly low blood pressure) and chest pain.

Overdose may escalate to severe or life-threatening outcomes, including cardiac arrest, persistent second- or third-degree atrioventricular (AV) block requiring intervention, and serious cerebrovascular events such as stroke or transient ischemic attack (TIA).

When to Seek Urgent Help

Immediate medical attention is mandated by official regulatory documents for any suspected or confirmed overdose. Contacting emergency services is required upon the occurrence of any life-threatening cardiorespiratory signs or symptoms that are severe or persistent.

Management of overdose is officially described as symptomatic and supportive. Regulatory labels confirm that aminophylline may be administered as a partial or complete antagonist to counteract the excessive effects of Regadenoson, particularly in cases of severe hypotension or persistent AV block. Following an overdose, patients may require hospitalization and continuous monitoring of vital signs, including cardiac rhythm and blood pressure, until their condition stabilizes.

Therapeutic Uses of Lexiscan

What Lexiscan Treats: Main Uses and Benefits

Lexiscan (Regadenoson) is a specialized agent used exclusively to facilitate diagnostic imaging. Its primary benefit is enabling a critical cardiac test for patients with physical limitations. Lexiscan is commonly used as a pharmacologic stress agent to facilitate radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

The agent may be used in conditions presenting with acute or disruptive episodes and conditions involving episodic or fluctuating manifestations, such as those suggestive of Coronary Artery Disease (CAD). It is considered relevant for patients who require the evaluation of blood flow to the heart muscle, and in clinical settings that involve prognostic assessment and cardiac risk stratification before major non-cardiac surgery. The use of Lexiscan supports the provision of key diagnostic information, which may assist in guiding subsequent management for patients experiencing symptoms that interfere with daily functioning.

“The clinical benefit may include providing a non-exercise alternative for cardiac evaluation.”

Quick Fact: Support for Cardiac Assessment The agent supports patients during episodes of heightened discomfort by offering a path to assessment for patients with mobility issues or poor physical conditioning.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lexiscan?

Lexiscan (Regadenoson) is strictly contraindicated and must not be administered to patients diagnosed with second- or third-degree atrioventricular (AV) block or sinus node dysfunction, unless they have a functioning artificial pacemaker. Its use must be avoided in individuals exhibiting symptoms or signs of acute myocardial ischemia, such as unstable angina.

Population Status Regulatory Rule
Established Use Adult patients (18 years and older) who are unable to undergo adequate exercise stress.
Use Not Established Pediatric population (under 18 years): Safety and effectiveness have not been established.
Organ Function No dose adjustment is needed for patients with renal impairment or hepatic impairment.
Pregnancy Not recommended unless clearly needed; use is only permitted under necessary circumstances.
Lactation Advise mother to pump and discard breast milk for 10 hours following administration, or discontinue the drug.
Conditional Use Caution is required for patients with known or suspected bronchoconstrictive disease (e.g., asthma or COPD), for whom appropriate resuscitative measures must be available.

Caution is also advised for older adult patients, as official data notes a higher likelihood of hypotension in this group.

What should I know about interactions with other medicines?

The official regulatory documents specify several interaction-related constraints required to maintain the diagnostic accuracy of the myocardial perfusion imaging procedure.

Interaction Scope Constraint and Restriction
Pharmacodynamic Antagonism Substances in the methylxanthine class, including medicinal products (e.g., Theophylline, Aminophylline) and Caffeine (in food or beverage forms), are documented to interfere with Regadenoson's activity. Avoidance of these products for at least 12 hours before administration is required to prevent a false-negative diagnostic result.
Exposure-Modifying Agents The co-administration of Dipyridamole is considered an interaction with major clinical significance due to its potential to increase Regadenoson's activity. Official restrictions mandate that Dipyridamole must be withheld for at least 48 hours prior to administration.
Metabolic and Population Notes Regadenoson is officially documented as having no inhibitory effect on major Cytochrome P450 enzymes (e.g., CYP1A2, 3A4), indicating a low risk of altering the clearance of most co-administered drugs. Although increased drug exposure is noted in patients with renal impairment, official labeling states that no dose adjustment is necessary in this population.

The interaction profile is structured primarily around mandatory timing rules and prohibitions that address agents known to alter the product's primary pharmacodynamic function. This structure ensures that regulatory requirements preserve the integrity of the diagnostic test results.

Mechanism of Action

Selective A2 A Receptor Activation and Coronary Vasodilation

The drug functions as a highly selective agonist that binds specifically to the A2 A adenosine receptors. These receptors are located predominantly on the smooth muscle cells of the coronary arteries. This targeted interaction initiates a rapid cellular signaling cascade, which causes the smooth muscle cells to relax. This action results in substantial coronary vasodilation, meaning the blood vessels supplying the heart muscle widen significantly, producing a large, short-lived increase in blood flow.

Modulating Vascular Smooth Muscle Tone

The mechanism directly influences vascular smooth muscle tone by engaging the G-protein pathway linked to the A2 A receptors, causing the vessels to move to a state of maximal dilation. The drug demonstrates lower binding affinity for other adenosine receptor subtypes, such as A1, which focuses the physiological effect on the vascular system. This selective modulation of tone effectively redistributes blood flow within the heart muscle, producing a state of maximal coronary vasodilation. This physiological difference generates a blood flow distribution pattern necessary for assessing blood distribution.

Dosage and Administration Information

How to Use Lexiscan (Regadenoson)

Lexiscan is used exclusively as a diagnostic aid and must be administered according to a highly standardized, fixed-dose protocol within a specialized clinical environment. The agent is employed only as a component of the Myocardial Perfusion Imaging (MPI) procedure.

Official Dosing and Administration Protocol

The following table outlines the protocol for dosing and administration for this agent.

Administration Detail Standard Instruction
Route of Administration Intravenous (IV) injection into a peripheral vein.
Standard Adult Dose A single, fixed dose of 0.4 mg (5 mL volume).
Dose Adjustment No adjustment is required based on body weight, or for patients with renal or hepatic impairment.
Frequency Used as a single diagnostic dose; permitted once within a 24-hour period.

Procedural Steps and Pre-Test Conditions

Administration involves a precise, timed sequence to facilitate the diagnostic test:

  1. The 0.4 mg dose must be injected rapidly over approximately 10 seconds.
  2. This injection is immediately followed by a 5 mL saline (0.9% sodium chloride) flush.
  3. The radionuclide imaging agent is then administered 10–20 seconds after the saline flush.

To ensure the integrity of the procedure, patients must avoid products containing methylxanthines (such as caffeine) for at least 12 hours prior to the procedure. The use of Lexiscan requires administration in a medical facility equipped with cardiac monitoring and resuscitation resources.

Recent Clinical Evidence

Lexiscan: Recent Clinical Evidence

Lexiscan (regadenoson) is a pharmacologic stress agent used in radionuclide myocardial perfusion imaging (MPI) for patients unable to undergo adequate exercise stress. Clinical research has primarily focused on establishing its efficacy and safety profile compared to adenosine, an older pharmacological agent.

Efficacy and Non-Inferiority

Pivotal Phase 3 trials, known as the ADVANCE MPI studies, compared Lexiscan to adenosine in patients with known or suspected coronary artery disease (CAD). These studies concluded that Lexiscan was non-inferior to adenosine in terms of diagnostic effectiveness for detecting the extent of reversible perfusion defects. This means the images produced using Lexiscan were consistent with those produced using adenosine, regardless of patient factors like age, gender, or presence of comorbidities.

Safety and Tolerability Profile

In clinical trials, Lexiscan generally demonstrated a favorable side effect profile compared to adenosine. Common adverse reactions reported (occurring in 5% or more of patients) were typically transient and included dyspnea (shortness of breath), headache, and flushing. These effects usually resolved within 15 to 30 minutes after administration.

However, regulatory agencies have issued warnings regarding the rare but serious risk of cardiac events, including myocardial infarction, ventricular arrhythmias, and cardiac arrest, which have been reported following the injection of Lexiscan, similar to other pharmacologic stress agents. These events underscore the need for careful patient screening and immediate availability of resuscitation equipment.

Combination and Alternative Use

Newer studies have explored using Lexiscan in combination with low-level exercise following an inadequate treadmill test. Research has suggested this approach may improve image quality and is generally well-tolerated. Other research has examined the feasibility of using Lexiscan in stress echocardiography and in magnetic resonance imaging (MRI) stress protocols, indicating continued research interest in expanding its application.

Key Studies & References Safety of regadenoson with low-level exercise stress in patients with known or suspected coronary artery disease

How should Lexiscan be stored and disposed of?

How to Store and Dispose of Lexiscan (Regadenoson)

Lexiscan injection must be stored at controlled room temperature, specifically 25 C (77 F), with permitted excursions between 15 C and 30 C. This product is supplied in single-dose syringes and must be kept in its original container until use.

Stability and Handling

Prior to administration, the solution must be visually inspected for any particulate matter or discoloration; the drug must not be administered if either is present. Lexiscan is for single-use only, and any portion remaining after use must be discarded immediately. As with all medications, it must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Lexiscan and associated waste must be disposed of according to local regulations for pharmaceutical waste. Disposal via standard household trash or wastewater is prohibited to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Lexiscan found in:

A-Z Index: